The application of a hybridisation-based next-generation sequencing (NGS) enrichment panel for the analysis of key genes involved in ovarian and breast tumours using DNA from FFPE samples

Monday 4 September 2017
Product types:
Applications:

Jacqueline Chan, Sabine Eckert, Lyudmila Georgieva and Graham Speight

Presented at the 2017 Cancer Genomics Consortium (CGC) annual summer meeting in Denver, USA, this poster illustrates the SureSeq™ hybridisation-based approach as a robust method for the identification of germline and somatic mutations in TP53, BRCA1, and BRCA2 and how it is possible to obtain important sequence information from as little as 50 ng of formalin-compromised DNA.

Want to download this as a PDF? Download now or preview the poster below.

Introduction

One of the challenges in cancer research is the high level of genetic complexity and tumour heterogeneity. Detailed information about the genetic profile of each individual tumour may help guide treatment strategies1 .

NGS has enabled the simultaneous study of multiple mutations in high-penetrance cancer predisposition genes. However, tissue biopsies are typically archived as formalin-fixed, paraffin embedded (FFPE) blocks which can significantly compromise the quality and amount of nucleic acids available for genomics research.

To overcome these issues, we have used the SureSeq FFPE DNA Repair Mix, in combination with a hybridisation-based NGS custom enrichment panel, the SureSeq Ovarian Cancer Panel (Table 1) to identify somatic variation in key DNA repair genes associated with ovarian cancer.

BRCA1 BRCA2 ATM TP53 ATR NF1 PTEN

Table 1: Key ovarian cancer-related genes in the SureSeq Ovarian Cancer Panel

To evaluate the application of a hybridisation-based approach we:

  • Compared the uniformity of coverage between a PCR-based and a hybridisation-based enrichment approach for the analysis of BRCA1 and BRCA2 in solid tumour samplesa
  • Identified potentially damaging variants in TP53, BRCA1 and BRCA2 genes from DNA extracted from FFPE blocks of type II epithelial ovarian cancer (EOC) samplesb.

SureSeq hybridisation workflow

The SureSeq hybridisation-based enrichment was used throughout this study; the workflow of this is outlined below in Figure 1.

OGT SureSeq NGS hybridisation workflowFigure 1: OGT SureSeq workflow. The SureSeq workflow allows users to go from extracted DNA to sequencer in 1.5 days with minimal handling time.

Formalin-damage in DNA can be reduced through use of FFPE DNA repair mix

We tested a range of FFPE-derived DNA and found pre-treatment with the SureSeq FFPE DNA Repair Mix significantly improves the mean target coverage, thereby increasing the flexibility of the assay (Figure 2A). Use of the Repair mix also enables a reduced DNA input down to 50 ng to be used (if necessary) whilst maintaining a good depth of coverage (Figure 2B).

Example data obtained using FFPE DNA extracted from ovarian cancer research samplesFigure 2: Example data obtained using FFPE DNA extracted from ovarian cancer research samples. Panel A shows that the SureSeq FFPE DNA Repair Mix improves on-target rate; Panel B demonstrates the Repair mix permits the use of lower DNA inputs whilst maintaining depth of coverage.

Hybridisation-based enrichment generates highly uniform coverage of key targets

To confidently call low frequency variants, NGS reads need to be evenly distributed across all regions of interest. Uniformity of coverage is a useful value with which to compare this distribution and can be expressed as the percentage of target bases that have >20% of the mean coverage.

As reported extensively in the literature1-3, we found the uniformity of coverage from hybridisation-based capture approaches such as SureSeq consistently outperform those enriched using amplicon-based methods (Figure 3). Furthermore, in our sample set we found that the high levels of uniformity are maintained even when starting with ~250 ng DNA (light blue bars).

The uniformity of coverage for most samples is >99% of bases covered at >20% of the mean, ensuring that all bases within the panel can be assessed confidently. In addition, the use of hybridisation-based capture instead of amplification-based enrichment allows the removal of PCR duplicates which can obscure the minor alleles present within a sample.

Assessment of the uniformity of sequencing coverage from FFPE-derived DNAFigure 3: Assessment of the uniformity of sequencing coverage from FFPE-derived DNA using an amplicon and the SureSeq hybridisation-based capture approaches. Enrichment by SureSeq (dark blue bars) demonstrates better uniformity than that of an amplicon-based approach (green bars). The level of uniformity is maintained with SureSeq when starting with ~250 ng DNA (light blue bars). Samples are ordered by increasing DNA Integrity Number (DIN) determined by Agilent 2200 TapeStation – value in brackets.

Confident detection of germline and somatic variants in key cancer-related genes

We tested 32 EOC samples determined by pathology to contain ≥40% tumour cells and identified one or more deleterious TP53 variant(s) with the minor allele frequencies (MAF) ranging from 1 to 80%. In addition to the mutations in TP53, several samples were found to have variants in BRCA1 and BRCA2 (Figures 6 and 7). Figures 4 – 7 were visualised using Integrated Genomics Viewer4 ; the grey vertical bars denote the depth of coverage per base, green horizontal bars the targeted region, and the red heatmap - the GC content.

This sample (DIN score 2.5) was found to contain a 2 bp deletion found in exon 10 of TP53Figure 4: This sample (DIN score 2.5) was found to contain a 2 bp deletion found in exon 10 of TP53 (transcript NM_ 000546).

This sample (DIN score 3.0) was found to have two potentially damaging variants in exon 8 of TP53Figure 5: This sample (DIN score 3.0) was found to have two potentially damaging variants in in exon 8 of TP53 - a germline SNV (rs28934576) and a single base deletion present at 3%.

TP53 exon 5 (panel A) and BRCA2 exon 11 (panel B). Figure 6: TP53 exon 5 (panel A) and BRCA2 exon 11 (panel B). This sample (DIN score 4.0) contains a 46% Pro151Ser SNV in TP53 and a 4 bp deletion of 71% allele frequency in BRCA2.

Shows uniformity of coverage in BRCA1 exon 11Figure 7: Shows uniformity of coverage in BRCA1 exon 11 (transcript NM_007294) – panel A. The evenness of coverage enables confident detection of seven variants, each of 60% allele frequency. This sample (DIN score 3.2) also had a 34% Arg273His mutation in TP53 (rs28934576) – panel B.

Conclusions

  • It is possible to obtain important sequence information from as little as 50 ng of formalincompromised DNA. 
  • Superior uniformity of coverage was demonstrated using a hybridisation-based enrichment approach. 
  • High levels of uniformity were maintained across a range of starting DNA input amounts in formalin-compromised DNA. 
  • The SureSeq hybridisation-based approach is a robust method for the identification of germline and somatic mutations in TP53, BRCA1, and BRCA2 from type II EOC tissue samples.

References

  1. Ross, J.S. and Cronin, M., 2011. Whole cancer genome sequencing by next-generation methods. American journal of clinical pathology, 136(4), pp.527- 539. 
  2. Kurman, R.J. and Ie-Ming, S., 2010. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. The American journal of surgical pathology, 34(3), pp.433-443. 
  3. Samorodnitsky, E., Jewell, B.M., Hagopian, R., Miya, J., Wing, M.R., Lyon, E., Damodaran, S., Bhatt, D., Reeser, J.W., Datta, J. and Roychowdhury, S., 2015. Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing. Human mutation, 36(9), pp.903-914. 
  4. Thorvaldsdóttir, H., Robinson, J.T. and Mesirov, J.P., 2013. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Briefings in bioinformatics, 14(2), pp.178-192.

Acknowledgements

Samples kindly provided by –

a Prof. Charlie Gourley (Cancer Research UK Edinburgh Centre)

b Prof. Rober Zeillinger and Dr. Nicole Concin (Medical University of Vienna and Medical University, Dept. of Gynecology and Obstetrics, Vienna, Austria)

SureSeq: For research use only; not for use in diagnostic procedures.

Request a technical consultation

Do you have a question about what you've just read? Contact us today and one of our technical specialists will be happy to answer any questions you may have.

Request a technical consultation >

Download literature

Download a PDF of this literature.

Download Literature